-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $97

Benzinga·08/11/2026 15:45:54
Listen to the news
Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowers the price target from $98 to $97.